Back to User profile » Dr Melissa Toyos
Papers published by Dr Melissa Toyos:
Perspectives of Healthcare Professionals on the Treatment Landscape of Ocular Redness
Toyos MM, Forster K, Savar S, Aguado S, Kiskiras K, Akbas E, DiVito M, Ryan R, Gallop K, Boboridis K, Salgado-Borges JM, Alio JL
Patient Preference and Adherence 2026, 20:591670
Published Date: 11 February 2026
Evaluation of the Safety and Tolerability of Lumify Eye Illuminations Cosmetic Products
Wesley G, Toyos MM, DiVito MM, Zirwas M
Clinical Ophthalmology 2024, 18:3031-3042
Published Date: 26 October 2024
Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies
Gupta PK, Toyos R, Sheppard JD, Toyos M, Mah FS, Bird B, Theriot PE, Higgins D
Clinical Ophthalmology 2024, 18:2283-2302
Published Date: 16 August 2024
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI
Clinical Ophthalmology 2022, 16:4145-4151
Published Date: 13 December 2022
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2019, 13:215-216
Published Date: 24 January 2019
A Phase II /III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:2637-2638
Published Date: 14 December 2018
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI
Clinical Ophthalmology 2018, 12:1921-1929
Published Date: 2 October 2018
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:913-914
Published Date: 17 May 2018
Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
Nichols KK, Holland E, Toyos MM, Peace JH, Majmudar P, Raychaudhuri A, Hamdani M, Roy M, Shojaei A
Clinical Ophthalmology 2018, 12:263-270
Published Date: 31 January 2018